MyFinsight
Home
Blog
About
Restricted cash
$8,000,000
Prepaid expenses
$2,235,996
(38.52%↑ Y/Y)
Cash and cash
equivalents
$278,371
(-96.81%↓ Y/Y)
Due from related
parties
$115,570
Other current assets
$48,501
Property and equipment,
at cost
$66,727
Digital assets, at fair
value
$116,737,168
Total current assets
$10,678,438
(3.18%↑ Y/Y)
Operating lease right of
use asset, net
$156,162
Property and equipment,
net
$51,929
(295.29%↑ Y/Y)
Less accumulated
depreciation
$14,798
Total assets
$127,623,697
(1110.08%↑ Y/Y)
Total liabilities and
shareholders equity
$127,623,697
(1110.08%↑ Y/Y)
Total shareholders
equity (deficit)
$106,448,541
(993.16%↑ Y/Y)
Total liabilities
$21,175,156
(2517.44%↑ Y/Y)
Accumulated deficit
-$65,626,043
(-780.12%↓ Y/Y)
Additional paid-in capital
$168,436,065
(886.83%↑ Y/Y)
Total current
liabilities
$21,073,283
(2504.85%↑ Y/Y)
Long-term portion of
operating lease liability
$101,873
Common shares to be
issued
$3,636,262
Common stock, par value
0.001, 100,000,000...
$1,509
(-98.80%↓ Y/Y)
Preferred stock, par value
0.001, 10,000,000...
$748
Convertible notes, net
$8,907,026
Notes payable, net
$5,000,000
Accounts payable and
accrued expenses
$3,221,643
(2604.13%↑ Y/Y)
Derivative liability
$1,352,641
Accrued interest
$1,200,000
Accrued offering costs
$780,000
Notes payable -
related party
$500,100
(0.02%↑ Y/Y)
Operating lease liability
$59,523
Accrued interest
related party
$40,350
Advance payable to
related party
$12,000
(11900.00%↑ Y/Y)
Back
Back
Balance Sheet
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)
source: myfinsight.com